Infliximab for Induction and Maintenance.pdfVIP

original article The new england journal of medicine n engl j med 353;23 december 8, 2005 2462 Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis Paul Rutgeerts, M.D., Ph.D., William J. Sandborn, M.D., Brian G. Feagan, M.D., Walter Reinisch, M.D., Allan Olson, M.D., Jewel Johanns, Ph.D., Suzanne Travers, M.D., Daniel Rachmilewitz, M.D., Stephen B. Hanauer, M.D., Gary R. Lichtenstein, M.D., Willem J.S. de Villiers, M.D., Ph.D., Daniel Present, M.D., Bruce E. Sands, M.D., and Jean Frédéric Colombel, M.D. From the University Hospital Gasthuis- berg, Leuven, Belgium (P.R.); Mayo Clinic, Rochester, Minn. (W.J.S.); Robarts Research Institute, University of Western Ontario, London, Ont., Canada (B.G.F.); Univer- sit?tsklinik für Innere Medizin IV, Allge- meines Krankenhaus Wien, Vienna (W.R.); Centocor, Malvern, Pa. (A.O., J.J., S.T.); Shaare Zedak Medical Center, Jerusalem, Israel (D.R.); University of Chicago, Chica- go (S.B.H.); University of Pennsylvania, Philadelphia (G.R.L.); University of Ken- tucky, Lexington (W.J.S.V.); Mount Sinai Medical Center, New York (D.P.); Massa- chusetts General Hospital, Boston (B.E.S.); and H?pital Huriez–Centre d’Investiga- tion Clinique INSERM Centre Hospitalier et Universitaire de Lille, Lille, France (J.F.C.). Address reprint requests for the Active Ul- cerative Colitis Trial 1 (ACT 1) to Dr. Rut- geerts at the Universitaire Ziekenhuizen Leuven, Inwendige Geneeskunde, UZ Gast- huisberg, Herestraat 49, B-3000 Leuven, Belgium, or at paul.rutgeerts@uz.kuleuven. ac.be. Address reprint requests for the Ac- tive Ulcerative Colitis Trial 2 (ACT 2) to Dr. Sandborn at the Mayo Clinic, 200 First St. SW, Rochester, MN 55905, or at sandborn. william@. Drs. Rutgeerts and Sandborn contributed equally to the article. N Engl J Med 2005;353:2462-76. Copyright ? 2005 Massachusetts Medical Society. background Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor